Publikationen in Zusammenarbeit mit Forschern von Memorial Sloan Kettering Cancer Center (12)

2024

  1. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

    Cancer cell, Vol. 42, Núm. 9, pp. 1614-1629

2023

  1. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

    Blood, Vol. 141, Núm. 18, pp. 2194-2205

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Epigenetic reprogramming sensitizes immunologically silent EBV1 lymphomas to virus-directed immunotherapy

    Blood, Vol. 135, Núm. 21, pp. 1870-1881

2019

  1. Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL

    Nature Communications, Vol. 10, Núm. 1

  2. Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia

    Nature, Vol. 569, Núm. 7757, pp. 576-580

  3. Somatic mutations and cell identity linked by Genotyping of Transcriptomes

    Nature, Vol. 571, Núm. 7765, pp. 355-360

2017

  1. Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers

    Cancer Discovery, Vol. 7, Núm. 8, pp. 868-883

2007

  1. Sphingolipids and cell death

    Apoptosis, Vol. 12, Núm. 5, pp. 923-939

2003

  1. Sphingomyelinase activity causes transbilayer lipid translocation in model and cell membranes

    Journal of Biological Chemistry, Vol. 278, Núm. 39, pp. 37169-37174

2002

  1. Role of sphingomyelinase and ceramide in modulating rafts: Do biophysical properties determine biologic outcome?

    FEBS Letters

2000

  1. Compartmentalization of Ceramide Signaling: Physical Foundations and Biological Effects

    Journal of Cellular Physiology, Vol. 184, Núm. 3, pp. 285-300